Rockwell Medical Inc. said the State Intellectual Property Office of the People’s Republic of China (SIPO) has accepted patent claims relating to ESA sparing, compositions and use for Triferic.
The claims allowed in the patent application, entitled “Methods of Treating Iron Deficiency with Soluble Ferric Pyrophosphate” include composition of matter and use of soluble ferric pyrophosphate to reduce ESA usage using hemodialysis solution with the specific dose. The patent provides protection through February 2034.
“We are thrilled to receive this important patent and the valuable IP protection it provides in the Chinese market,” said Robert L. Chioini, chairman and CEO of Rockwell. “We view China as a key strategic dialysis market that we anticipate may become the world’s largest over the next several years.”